JP2008507536A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507536A5
JP2008507536A5 JP2007522697A JP2007522697A JP2008507536A5 JP 2008507536 A5 JP2008507536 A5 JP 2008507536A5 JP 2007522697 A JP2007522697 A JP 2007522697A JP 2007522697 A JP2007522697 A JP 2007522697A JP 2008507536 A5 JP2008507536 A5 JP 2008507536A5
Authority
JP
Japan
Prior art keywords
composition
angptl4
antagonist
antibody
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007522697A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507536A (ja
JP4947717B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025734 external-priority patent/WO2006014729A2/en
Publication of JP2008507536A publication Critical patent/JP2008507536A/ja
Publication of JP2008507536A5 publication Critical patent/JP2008507536A5/ja
Application granted granted Critical
Publication of JP4947717B2 publication Critical patent/JP4947717B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007522697A 2004-07-20 2005-07-19 アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用 Expired - Fee Related JP4947717B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58978204P 2004-07-20 2004-07-20
US60/589,782 2004-07-20
PCT/US2005/025734 WO2006014729A2 (en) 2004-07-20 2005-07-19 Inhibitors of angiopoietin-like 4 protein, combinations, and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011175420A Division JP2012017331A (ja) 2004-07-20 2011-08-10 アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2008507536A JP2008507536A (ja) 2008-03-13
JP2008507536A5 true JP2008507536A5 (OSRAM) 2008-08-07
JP4947717B2 JP4947717B2 (ja) 2012-06-06

Family

ID=35787710

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007522697A Expired - Fee Related JP4947717B2 (ja) 2004-07-20 2005-07-19 アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用
JP2011175420A Withdrawn JP2012017331A (ja) 2004-07-20 2011-08-10 アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011175420A Withdrawn JP2012017331A (ja) 2004-07-20 2011-08-10 アンジオポエチン様4タンパク質のインヒビター、組み合わせ、およびそれらの使用

Country Status (23)

Country Link
US (2) US7740846B2 (OSRAM)
EP (3) EP1771474B1 (OSRAM)
JP (2) JP4947717B2 (OSRAM)
KR (1) KR101254815B1 (OSRAM)
CN (2) CN101044164A (OSRAM)
AT (1) ATE456579T1 (OSRAM)
AU (2) AU2005269716B2 (OSRAM)
BR (1) BRPI0513534A (OSRAM)
CA (1) CA2574758A1 (OSRAM)
CY (1) CY1109931T1 (OSRAM)
DE (1) DE602005019167D1 (OSRAM)
DK (1) DK1771474T3 (OSRAM)
ES (1) ES2339789T3 (OSRAM)
IL (1) IL180725A0 (OSRAM)
MX (1) MX2007000784A (OSRAM)
NO (1) NO20070951L (OSRAM)
NZ (1) NZ552956A (OSRAM)
PL (1) PL1771474T3 (OSRAM)
PT (1) PT1771474E (OSRAM)
RU (1) RU2392966C2 (OSRAM)
SI (1) SI1771474T1 (OSRAM)
WO (1) WO2006014729A2 (OSRAM)
ZA (1) ZA200701183B (OSRAM)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7883720B2 (en) 2003-07-09 2011-02-08 Wisconsin Alumni Research Foundation Charge-dynamic polymers and delivery of anionic compounds
KR20070061524A (ko) * 2004-07-20 2007-06-13 제넨테크, 인크. 안지오포이에틴-유사 4 단백질을 사용하는 조성물 및 방법
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
EP1846452B1 (en) * 2005-01-07 2014-08-06 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )
US8734851B2 (en) * 2005-04-29 2014-05-27 Wisconsin Alumni Research Foundation Localized delivery of nucleic acid by polyelectrolyte assemblies
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
KR100962301B1 (ko) * 2006-11-03 2010-06-11 재단법인서울대학교산학협력재단 자궁경부암을 위한 치료용 조성물
BRPI0720552A2 (pt) * 2006-12-19 2014-01-07 Genentech Inc Antagonistas específicos de vegf para terapia adjuvante e neoadjuvante e o tratamento de tumores em estágio precoce
US8834918B2 (en) * 2007-01-22 2014-09-16 Wisconsin Alumni Research Foundation Modified multilayered film
CN101842095B (zh) * 2007-07-02 2015-06-24 于明 肿瘤治疗的配方,方法和靶目标
US20090105375A1 (en) * 2007-10-09 2009-04-23 Lynn David M Ultrathin Multilayered Films for Controlled Release of Anionic Reagents
US8126437B1 (en) 2008-01-24 2012-02-28 Invent Again Ubiquitous voice messaging
US8324333B2 (en) 2008-06-05 2012-12-04 Wisconsin Alumni Research Foundation Anionic charge-dynamic polymers for release of cationic agents
NZ594540A (en) * 2008-07-16 2012-01-12 Baylor Res Inst Hiv vaccine based on targeting maximized gag and nef antigen to dendritic cells using antibodies
US20100143351A1 (en) 2008-11-22 2010-06-10 Genentech, Inc. Anti-Angiogenesis Therapy for the Treatment of Breast Cancer
CN105412094A (zh) 2009-07-06 2016-03-23 爱尔皮奥治疗有限公司 用于防止癌细胞转移的化合物、组合物和方法
WO2011046515A1 (en) * 2009-10-14 2011-04-21 Nanyang Technological University Antiproliferative agent
EP2521556B1 (en) 2010-01-08 2018-05-30 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
US9139629B2 (en) 2010-06-05 2015-09-22 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
US9475850B2 (en) 2010-06-05 2016-10-25 The Uab Research Foundation Methods for treatment of nephrotic syndrome and related conditions
ES2877629T3 (es) * 2010-07-12 2021-11-17 Immunogenesis Inc Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer
US20140004209A1 (en) 2010-12-22 2014-01-02 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
EP2734199B1 (en) 2011-07-22 2022-11-16 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
EP2742361A4 (en) * 2011-08-08 2015-03-04 Univ Nanyang Tech ANGIOPOIETIN LIKE 4 AND ITS USE FOR MODULATION OF CELL OVERNIGHTNESS
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
BR112014032346A2 (pt) 2012-06-26 2017-06-27 Del Mar Pharmaceuticals métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
WO2014027959A1 (en) * 2012-08-14 2014-02-20 Nanyang Technological University Angiopoietin-like 4 antibody and a method of its use in cancer treatment
US9259435B2 (en) 2012-08-31 2016-02-16 W. L. Gore & Associates, Inc. Reactive oxidative species generating materials and methods of use
RU2676697C2 (ru) * 2012-10-30 2019-01-10 Пасилекс Фармасьютикалз Инк. Синтетическая летальность и лечение рака
KR101407730B1 (ko) * 2012-11-23 2014-06-12 인하대학교 산학협력단 안지오포이에틴-4 단백질을 유효성분으로 포함하는 발기부전의 예방 또는 치료용 조성물
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014251038A1 (en) 2013-04-08 2015-11-26 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
US9127276B2 (en) 2013-05-01 2015-09-08 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
KR102298476B1 (ko) 2013-12-24 2021-09-03 아이오니스 파마수티컬즈, 인코포레이티드 안지오포이에틴-유사 3 발현의 조절
EP3116503A4 (en) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta inhibitors
CN106255755B (zh) 2014-05-01 2020-07-24 Ionis制药公司 用于调节血管生成素样蛋白3表达的组合物和方法
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
DK3325662T3 (da) 2015-07-17 2023-11-27 Pacylex Pharmaceuticals Inc Epigenetisk inaktivering af nmt2
ES2981607T3 (es) 2015-09-23 2024-10-09 Eyepoint Pharmaceuticals Inc Activadores de Tie-2 para uso en el tratamiento de la presión intraocular
CN106596979B (zh) * 2017-02-28 2018-10-09 汉氏联合(天津)干细胞研究院有限公司 一种用于帕金森综合症检测的试剂盒及其检测方法
WO2020099478A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl4 oligonucleotides influencing the regulation of the fatty acid metabolism
AU2020264969B2 (en) 2019-04-29 2025-06-05 EyePoint Pharmaceuticals, Inc. Tie-2 activators targeting the schlemm's canal
CN119607006A (zh) * 2019-12-09 2025-03-14 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
CN112611877B (zh) * 2020-12-31 2022-09-16 四川大学华西医院 一款利用angptl4预测急性呼吸窘迫综合征患病及预后的试剂盒
CN113797355B (zh) * 2021-10-14 2023-07-21 四川大学华西医院 具有滑膜炎症抑制功能的纳米材料的制备方法及应用
WO2025040097A1 (zh) * 2023-08-22 2025-02-27 成都先衍生物技术有限公司 一种靶向ANGPTL4的siRNA及其缀合物和用途
CN119405811A (zh) * 2024-11-13 2025-02-11 杭州师范大学 禁食诱导因子Angptl4蛋白作为分子靶点在治疗或预防压力性脱发中的应用

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル,インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン コーポレーション Hiv感染治療のための異種複合抗体
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
RU2170589C2 (ru) * 1992-10-28 2001-07-20 Генентек Инк. Композиция для ингибирования ангиогенеза, моноклональное антитело, полипептид, способ ингибирования роста опухоли (варианты)
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5641756A (en) 1993-07-27 1997-06-24 Hybridon, Inc. Modified VEGF oligonucleotides
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US20030207375A1 (en) 1997-10-24 2003-11-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1931599A (en) 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
EP1058737A4 (en) 1998-03-02 2003-01-02 Millennium Pharm Inc NOVEL FDRG PROTEIN AND NUCLEIC ACID MOLECULES AND USE OF SUCH MOLECULES
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2000003797A1 (de) 1998-07-15 2000-01-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Polyelektrolythüllen auf biologischen templaten
US6375447B1 (en) 1998-09-29 2002-04-23 Cq Inc. Apparatus for dewatering and pelletizing particulate fuel
WO2001053455A2 (en) 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
JP2000308488A (ja) 1999-02-23 2000-11-07 Herikkusu Kenkyusho:Kk 血管新生に関連するタンパク質および該タンパク質をコードする遺伝子
WO2000052165A2 (en) 1999-03-04 2000-09-08 Corixa Corporation Compositions and methods for breast cancer therapy and diagnosis
AU4200900A (en) 1999-04-09 2000-11-14 Human Genome Sciences, Inc. 49 human secreted proteins
DE60041367D1 (de) 1999-04-16 2009-02-26 Genentech Inc Vaskuläre Endothelzellen Wachstumsfaktor (VEGF) Varianten und dessen Verwendungen
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
WO2001002429A2 (en) 1999-07-02 2001-01-11 Bayer Aktiengesellschaft Angiopoietin-6 and uses thereof
AU6605900A (en) 1999-07-16 2001-02-05 Hyseq, Inc. Novel angiopoietin materials and methods
US20030207348A1 (en) 1999-07-20 2003-11-06 Shimkets Richard A. Polypeptides and polynucleotides encoding same
CA2379925A1 (en) 1999-07-20 2001-01-25 Curagen Corporation Polypeptides and polynucleotides encoding same
AU2001233041A1 (en) 2000-01-25 2001-08-07 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
CN1315451A (zh) 2000-03-29 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人血管形成素类似因子45和编码这种多肽的多核苷酸
AU2001249929A1 (en) 2000-04-07 2001-10-23 Dana-Farber Cancer Institute Inc. Fdrg proteins and nucleic acid molecules and uses therefor
HRP20030041A2 (en) 2000-06-23 2005-02-28 Schering Aktiengesellschaft Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor fuction and their use (ii)
US6673545B2 (en) 2000-07-28 2004-01-06 Incyte Corporation Prostate cancer markers
CN1170850C (zh) 2000-09-19 2004-10-13 上海市肿瘤研究所 人血管生成素样蛋白和编码序列及其用途
US20040249141A1 (en) 2000-10-16 2004-12-09 Audrey Goddard Tie ligand homologues
EP1408759A4 (en) 2001-03-27 2005-04-06 Human Genome Sciences Inc SEPARATE HUMAN PROTEINS
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US7667004B2 (en) * 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
JP2005502322A (ja) 2001-04-19 2005-01-27 ザ スクリップス リサーチ インスティテュート 非天然アミノ酸のインビボ組込み
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
CA2450022A1 (en) 2001-06-08 2002-12-19 Sankyo Company, Limited Method of testing drug for treating or preventing diseases such as hyperlipemia
WO2003010205A1 (en) 2001-07-26 2003-02-06 Duke University Medical Center Genes induced by hypoxia
AU2002330039A1 (en) 2001-09-17 2003-04-01 Eos Biotechnology, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003040330A2 (en) 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20040038230A1 (en) 2001-11-05 2004-02-26 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素-样蛋白质3angptl3的组合物及其使用方法
AU2002359464A1 (en) 2001-11-30 2003-06-17 Genvec, Inc. Angiopioetin related factors
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US20050239706A1 (en) 2003-10-31 2005-10-27 Washington University In St. Louis Modulation of fiaf and the gastrointestinal microbiota as a means to control energy storage in a subject
CA2499791A1 (en) 2004-03-30 2005-09-30 F. Hoffmann-La Roche Ag Angptl4/fiaf as marker for ppardelta modulation
SI1771474T1 (sl) 2004-07-20 2010-06-30 Genentech Inc Inhibitorji angiopoetinu podobnega proteina kombinacije in njihova uporaba
KR20070061524A (ko) 2004-07-20 2007-06-13 제넨테크, 인크. 안지오포이에틴-유사 4 단백질을 사용하는 조성물 및 방법
EP1846452B1 (en) 2005-01-07 2014-08-06 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angiopoietin-like protein 4 (angptl4 )

Similar Documents

Publication Publication Date Title
JP2008507536A5 (OSRAM)
JP2012067116A5 (OSRAM)
CN110996952A (zh) 用于治疗癌症的方法
KR20120104547A (ko) 조 합 물
CN113209102A (zh) 包含n-(3,5-二甲氧基苯基)-n’-(1-甲基乙基)-n-[3-(1-甲基-1h-吡唑-4-基)喹喔啉-6-基]乙烷-1,2-二胺的药物组合物
CN108697661A (zh) 用于治疗癌症的组合
JP6425653B2 (ja) 抗腫瘍剤及び抗腫瘍効果増強剤
JP2011503039A5 (OSRAM)
CN114224889A (zh) 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
US20230226040A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
JP7642556B2 (ja) 併用医薬
JP2013503842A5 (OSRAM)
Gaspar et al. Bone sarcomas: from biology to targeted therapies
TWI454280B (zh) Pharmaceutical composition or combination
JP2005511663A5 (OSRAM)
EP4475847A1 (en) An igf1r inhibitor and an akt inhibitor for use in the treatment of cancer
JP2013540725A5 (OSRAM)
JP2020528418A (ja) BET阻害剤及びBcl−2阻害剤を用いた併用療法
AU2020209767B2 (en) Method for treating an acute myeloid leukemia
JP2016521760A (ja) がんの処置のための、ro5503781、カペシタビン及びオキサリプラチンの組み合わせ
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
TWI547286B (zh) 趨化激素受體拮抗劑及其組合療法
WO2020198705A1 (en) Combinations useful in a method for treating sarcoma